Changes in cytokine production during therapy with Granulocyte‐macrophage colony‐stimulating factor in patients with chronic hepatitis B
Julio Martín, Juan A. Quiroga, Orencio Bosch, Vicente Carreño – 1 November 1994 – Recombinant human granulocyte‐macrophage colony‐stimulating factor therapy significantly reduces serum hepatitis B virus DNA levels, associated with increased 2′, 5′‐oligoadenylate synthetase activity in cultured mononuclear cells of patients with chronic hepatitis B.